Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been selected by the United Kingdom’s Government Innovation Agency (Innovate UK) to participate in the prestigious UK Antimicrobial Resistance Inward Mission 2024.
This event, set to take place from June 2-7, 2024, will spotlight Recce as one of 18 promising organisations from across the globe recognised for their potential to combat antimicrobial resistance (AMR).
Innovate UK’s rigorous selection process identified Recce from a large competitive pool of international candidates — from Australia, Canada, France, India, Italy, Netherlands, Nigeria, Norway, Switzerland and USA — highlighting its innovative approach and potential to synergise with the UK’s AMR industry leaders.
About Inward Mission 2024
The UK AMR Inward Mission 2024 will host a comprehensive program, including partnering sessions, visits to world-class AMR infrastructure, and interactions with key opinion leaders.
A highlight of the event will be a reception in Cambridge with Professor Dame Sally Davies, former England Chief Medical Officer who acted as the UK government’s principal medical adviser and the professional head of all directors of public health in local government.
Recce says its selection for the UK AMR Inward Mission presents an important geographic opportunity in its global strategy, particularly in establishing a foothold in the UK’s vibrant AMR research and development ecosystem.
This engagement will enable Recce to forge essential partnerships, gain insights into regulatory pathways, and explore new markets, ultimately advancing its mission to provide innovative solutions to the pressing global health challenge of AMR.
"Catalyst for our continued growth"
Recce Pharmaceuticals CEO James Graham said, "We are thrilled by the opportunity to collaborate with the UK’s leading AMR experts and institutions and thank the UK Government for their support.
"We believe this mission will be a catalyst for our continued growth and success in developing life-saving antimicrobial treatments.”